

What Clinicians Want to Know: Understanding the Factors Affecting the Optimal Diagnosis and Management of Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the maximum duration of treatment with olaparib in the Phase III SOLO-1 trial evaluating PARP inhibitor maintenance therapy after debulking surgery and first-line platinum-based chemotherapy for patients with advanced ovarian cancer?**
  - a. One year
  - b. Two years**
  - c. Three years
- 2. Which patients with ovarian cancer were eligible for enrollment in the SOLO-1 trial?**
  - a. All patients, regardless of BRCA mutation status
  - b. Only patients with homologous recombination deficiency-positive disease
  - c. Only patients with BRCA1/2 mutations**
- 3. Which of the following PARP inhibitors is FDA approved in combination with bevacizumab as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer, based on the PAOLA-1 study?**
  - a. Olaparib**
  - b. Niraparib
  - c. Rucaparib
  - d. Veliparib
- 4. Which side effect is generally associated with PARP inhibitors?**
  - a. Neurologic symptoms
  - b. Gastrointestinal symptoms**
  - c. Alopecia
- 5. What is the approximate incidence of myelodysplastic syndromes or acute myeloid leukemia among patients who receive PARP inhibitors?**
  - a. 1%**
  - b. 5%
  - c. 10%
  - d. Unknown